# Mold illness and CIRS

Rating: Speculative — Little primary evidence yet: mechanism, anecdote or tradition
Type: Condition
Updated: 2026-10-15
Canonical: https://heretic.bio/articles/mold-illness-mycotoxins-and-cirs.html

> CIRS is a proposed multisystem illness in which genetically susceptible people (about 25% by HLA type) fail to clear biotoxins from water-damaged buildings, driving chronic innate inflammation. The solid part: damp buildings cause illness across 112 of 114 epidemiological studies and mycotoxins are demonstrably toxic. The contested part: the diagnostic biomarker panel, urine mycotoxin testing and the 12-step Shoemaker treatment protocol come almost entirely from one research group, and toxicology bodies question the commercial testing.

## Overview

**Chronic Inflammatory Response Syndrome (CIRS)** is a multisymptom, multisystem illness caused by dysregulation of the innate immune system following exposure to biotoxins — most commonly from **water-damaged buildings (WDBs)** containing mold, actinobacteria, and other microorganisms. It is not an IgE-mediated allergy. Instead, it reflects a failure of the innate immune system to clear biotoxins in genetically susceptible individuals (~25% of the population), leading to chronic systemic inflammation.

The condition was identified by **Ritchie Shoemaker, MD** in 1997 during a _Pfiesteria_ outbreak in Maryland waterways, and later extended to mold-exposed patients. A 2024 literature review found that the **Shoemaker Protocol** — centered on cholestyramine, removal from exposure, and intranasal VIP — is the only treatment in the published literature with documented clinical efficacy for CIRS (Dooley et al., 2024; PMID: [39649915](https://pubmed.ncbi.nlm.nih.gov/39649915/)).

> ⚠️ **Controversy Status:** CIRS remains contested in mainstream medicine. Chang & Gershwin (2019) concluded the evidence does not support "toxic mold syndrome" as a diagnostic entity, and criticized commercial mycotoxin testing labs as lacking scientific credibility. The American College of Medical Toxicology (2025) issued a position statement questioning the validity of urine mycotoxin testing. Meanwhile, a growing body of peer-reviewed literature — including transcriptomic and neuroimaging studies — supports a reproducible immune dysregulation pattern. Apply the Source Evaluation Framework rigorously: separate what is well-established (damp buildings cause illness) from what remains debated (specific diagnostic markers, treatment protocols).

* * *

## The CIRS Disease Model

### Core Mechanism

  1. **Exposure** → Inhalation of biotoxins (mycotoxins, bacterial endotoxins, actinobacterial cell wall components) from WDBs, or ingestion/exposure to marine biotoxins (ciguatera, _Pfiesteria_), tick-borne illness (Lyme), or cyanobacteria
  2. **Genetic susceptibility** → HLA DR/DQ haplotypes in ~25% of the population impair antigen presentation and biotoxin clearance
  3. **Innate immune activation** → Persistent elevation of inflammatory cytokines without adequate transition to adaptive immunity
  4. **Multisystem injury** → Neuroendocrine disruption, capillary hypoperfusion, mitochondrial dysfunction, neuroinflammation



### Key Biomarkers (Shoemaker Panel)

Biomarker | Direction | Significance  
---|---|---  
**MSH** (Melanocyte-Stimulating Hormone) | ↓ Low | Master regulator of neuroimmune function; low MSH drives hypothalamic dysfunction, ADH/ACTH dysregulation  
**TGF-β1** | ↑ Elevated | Profibrotic cytokine; tissue remodeling, immune suppression  
**MMP-9** | ↑ Elevated | Matrix metalloproteinase; tissue destruction, vascular leak  
**C4a** | ↑ Elevated | Complement activation product; innate immune activation marker  
**VEGF** | ↓ or fluctuating | Vascular endothelial growth factor; capillary hypoperfusion when low  
**ACTH/Cortisol** | Dysregulated | HPA axis disruption  
**ADH/Osmolality** | Dysregulated | Posterior pituitary dysfunction; frequent urination, thirst  
**VCS** (Visual Contrast Sensitivity) | ↓ Impaired | Functional neurotoxicity screen; biotoxin effects on optic nerve  
  
### Symptom Clusters

CIRS diagnosis (Shoemaker criteria) requires symptoms in **≥8 of 13 clusters** :

  1. Fatigue / lethargy
  2. Aches, cramps, unusual pain
  3. Weakness
  4. Memory / concentration (brain fog)
  5. Headache / light sensitivity
  6. Frequent urination / thirst (ADH dysregulation)
  7. Abdominal pain / diarrhea / nausea
  8. Joint pain / morning stiffness
  9. Mood swings / anxiety / depression
  10. Skin sensitivity / tingling / numbness
  11. Shortness of breath / sinus congestion
  12. Red eyes / blurred vision / tearing
  13. Night sweats / temperature dysregulation



> **McMahon (2017)** demonstrated that combining symptom cluster screening (≥8/13) with VCS deficit yielded **> 95% diagnostic accuracy** for CIRS-WDB, and up to 98.5% when combined with lab criteria.

* * *

## Mycotoxins: Mechanism of Injury

### Major Mycotoxins from Water-Damaged Buildings

Mycotoxin | Primary Producers | Mechanism of Toxicity  
---|---|---  
**Ochratoxin A (OTA)** | _Aspergillus_ , _Penicillium_ | Nephrotoxic, DNA damage, oxidative stress, protein synthesis inhibition  
**Aflatoxins (B1, B2, G1, G2)** | _Aspergillus flavus_ , _A. parasiticus_ | Hepatocarcinogenic (IARC Group 1), DNA adducts, p53 mutation  
**Trichothecenes (macro)** | _Stachybotrys chartarum_ ("black mold") | Protein synthesis inhibition, neurotoxicity, immune suppression  
**Fumonisins** | _Fusarium_ | Sphingolipid disruption, neural tube defects, esophageal cancer  
**Zearalenone** | _Fusarium_ | Estrogenic endocrine disruption  
**Gliotoxin** | _Aspergillus fumigatus_ | Immunomodulatory, apoptosis of immune cells  
  
### Non-Fungal Triggers in WDBs

Critically, **actinobacteria** (e.g., _Corynebacterium_ , _Streptomyces_) co-habit WDBs and produce potent inflammatory cell wall components (mycolic acids). Shoemaker et al. (2021) demonstrated that some CIRS patients have **negative ERMI scores** (no detectable mold DNA) but clear transcriptomic evidence of actinobacterial exposure — meaning mold-only testing misses a significant subset of environmentally triggered illness (Shoemaker et al., 2021; PMID: [39649915](https://pubmed.ncbi.nlm.nih.gov/39649915/) ref 35).

* * *

## Diagnostic Approach

### Stepwise Screening

  1. **Exposure history** → Water damage, visible mold, musty odor, known WDB occupation
  2. **Symptom cluster screen** → ≥8/13 clusters (95% sensitivity)
  3. **VCS test** → Online or in-office visual contrast sensitivity test (low-cost screen)
  4. **HLA DR/DQ genotyping** → Identifies genetic susceptibility haplotypes (~25% of population)
  5. **Biomarker panel** → MSH, TGF-β1, MMP-9, C4a, VEGF, ACTH/cortisol, ADH/osmolality
  6. **Environmental testing** → ERMI (Environmental Relative Moldiness Index) DNA-based dust analysis; HERTSMI-2 (simpler panel); consider actinobacterial testing when ERMI negative
  7. **Advanced** → NeuroQuant brain volumetric MRI (caudate atrophy, pallidum enlargement pattern); GENIE transcriptomic platform (ProgeneDx) for gene expression profiling



### ERMI and HERTSMI-2

  * **ERMI** — EPA-developed DNA-based assay using dust samples to quantify 36 mold species (MSQPCR). Scores >2 suggest elevated mold burden; >5 significant.
  * **HERTSMI-2** — Abbreviated 5-species panel (_Aspergillus ochraceus_ , _A. fumigatus_ , _Penicillium chrysogenum_ , _Stachybotrys chartarum_ , _Wallemia sebi_) developed for clinical decision-making. Scores >11 associated with CIRS risk.
  * **Limitation:** Neither panel detects actinobacteria, which may be the primary trigger in some patients.



### Contested Testing

  * **Urine mycotoxin testing** (e.g., RealTime Labs, Great Plains) — Commercially popular but **not independently validated**. ACMT (2025) and Chang & Gershwin (2019) question clinical utility. Results may reflect dietary mycotoxin exposure rather than tissue burden. Use with caution and never as sole diagnostic criteria.
  * **Provoked urine testing** — Even more contested; no standardized protocols or reference ranges.



* * *

## Treatment Approaches Studied

### Doses in studies

The Shoemaker Protocol is a sequential, stepwise approach. Each step addresses a specific physiological abnormality and is monitored by biomarkers. Do not skip ahead.

Step | Intervention | Target | Evidence  
---|---|---|---  
**1** | **Remove from exposure** | Eliminate ongoing biotoxin exposure | Critical; all other steps fail if exposure continues  
**2** | **Cholestyramine (CSM)** or **Colesevelam** | Bile acid sequestrant binds biotoxins in enterohepatic circulation | 2 RCTs (Level II), multiple case series (PMID: [17010568](https://pubmed.ncbi.nlm.nih.gov/17010568/))  
**3** | **Eradicate MARCoNS** (Multiple Antibiotic Resistant Coagulase Negative Staphylococci) | Nasal biofilm infection; EDTA nasal spray ± rifampin/bactroban | Case series  
**4** | **Correct ADH/osmolality** | Desmopressin if indicated | Clinical response  
**5** | **Correct elevated MMP-9** | Fish oil (omega-3), low-amylose diet | Biomarker normalization  
**6** | **Correct elevated C3a** | — | Case series  
**7** | **Correct elevated C4a** | Erythropoietin or ARB (losartan) | Case series  
**8** | **Correct VEGF** | Corrected automatically with steps 1-7 | —  
**9** | **Androgen support** | DHEA supplementation if low | Clinical  
**10** | **Correct antidiuretic hormone** | Desmopressin if persistently abnormal | Clinical  
**11** | **Lower elevated leptin** | Corrected with treatment | —  
**12** | **Intranasal VIP (Vasoactive Intestinal Peptide)** | Final step; restores neuroimmune regulation, reverses brain atrophy | Open-label trials (Level IV); PMID: [24946038](https://pubmed.ncbi.nlm.nih.gov/24946038/)  
  
### Cholestyramine — Primary Intervention

**Mechanism:** Bile acid sequestrant that binds biotoxins in the gut lumen, preventing enterohepatic recirculation and promoting fecal elimination.

**Evidence:** \- **2 RCTs** (Shoemaker, Level II): 8 patients and 13 patients respectively, both demonstrating significant symptom resolution and VCS improvement vs. placebo \- **Case-control study** (n=156 cases, 110 controls): Statistically significant biomarker normalization \- **Limitation:** All studies from Shoemaker group; independent replication is minimal

**Binding Specificity:** \- ✓ Effective: Ochratoxin A, fumonisins, zearalenone \- ✗ Weak binding: Aflatoxins, trichothecenes (including from _Stachybotrys_) \- ✓ Colesevelam (Welchol) as alternative for patients intolerant to CSM

**Side Effects:** Constipation (most common), acid reflux, interference with fat-soluble vitamin absorption (A, D, E, K) and medication absorption.

> **2024 crossover trial:** Cholestyramine 12 weeks reduced serum PFOS (perfluoroalkyl substance) by ~60%, demonstrating the bile-acid sequestration effect extends beyond mycotoxins to persistent organic pollutants (PMID: [38367552](https://pubmed.ncbi.nlm.nih.gov/38367552/)).

### Intranasal VIP — Final Step

**Mechanism:** Vasoactive intestinal peptide; anti-inflammatory neuropeptide that regulates innate immunity, vascular tone, and neuroimmune function.

**Evidence:** \- Ryan & Shoemaker (2016): RNA-Seq showed VIP therapy normalized transcriptomic profiles in 14 CIRS patients — suppressed inflammatory genes, restored ribosomal/mitochondrial gene expression (PMID: [25889530](https://pubmed.ncbi.nlm.nih.gov/25889530/)) \- Shoemaker et al. (2017): Serial MRI (NeuroQuant) demonstrated significant volumetric increases in grey matter nuclei (hippocampus, caudate, thalamus, putamen, pallidum, cerebellum); proportion of structures with atrophy fell below 1% \- Increased T regulatory cells (CD4+ CD25+) from 8.9% to 22.5% — indicating restoration of immunoregulatory function

**Availability:** Compounding pharmacy only; ~$300+/month; not insurance-covered.

**Cautions:** Must complete Steps 1–11 first; VIP in uncorrected patients can cause hypotension, flushing. Monitor blood pressure.

* * *

## Transcriptomic Advances (2015–2025)

The **GENIE** (Gene Expression: Inflammation Explained) platform uses Nanostring digital barcoding to profile gene expression, revealing a defining molecular hallmark of CIRS called **molecular hypometabolism (MHM)** :

  * **Suppression of ribosomal and mitochondrial genes** → impaired protein synthesis and cellular energy production
  * **Proliferative physiology** → IRS2 upregulation shunts pyruvate from oxidative phosphorylation to aerobic glycolysis (Warburg-like), producing less ATP and more lactate
  * **Triple-positive fingerprint** (TUBB1 + TUBA4A + CLU + coagulation genes) → detected in some CIRS patients; initially identified in Parkinson's disease; may represent an early, modifiable neurodegenerative risk signature
  * **Treatment trajectory** → GENIE tracks a predictable sequence (suppression → overshoot → correction → stability) called the "CIRS curve"



A 2025 review by Dooley traced the evolution from VCS testing → proteomic biomarkers → neuroimaging (NeuroQuant) → transcriptomics, arguing that CIRS offers a more reproducible diagnostic model than ME/CFS, which lacks validated biomarkers (PMID: [40806417](https://pubmed.ncbi.nlm.nih.gov/40806417/)).

### Post-COVID Connection

Shoemaker et al. (2021) applied GENIE profiling to Post-COVID Syndrome (PCS) patients and found overlapping transcriptomic signatures with CIRS-WDB: molecular hypometabolism, proliferative physiology, suppressed CD3D, and upregulated TGFBR1-3/CD14/TLR4. This raises the possibility that a subset of Long COVID patients may have CIRS-like immune dysregulation that is treatable.

* * *

## Evidence Summary and Skepticism

### What Is Well-Established (Tier 1–2)

Finding | Evidence Quality  
---|---  
Dampness and mold in buildings cause respiratory and systemic health effects | **Strong** — WHO guidelines (2009, PMID: [23785740](https://pubmed.ncbi.nlm.nih.gov/23785740/)); 112 of 114 epidemiological studies show association (Dooley & McMahon, 2020)  
~25% of the population has HLA haplotypes associated with impaired biotoxin clearance | **Moderate** — Consistent clinical observations; limited independent genetic validation  
Mycotoxins (aflatoxin, ochratoxin, trichothecenes) are toxic to humans at sufficient exposure | **Strong** — IARC classifications, occupational health data  
Cholestyramine binds certain mycotoxins in the GI tract | **Moderate** — Animal data + human pharmacology of bile acid sequestration  
  
### What Remains Contested (Tier 3–5)

Claim | Evidence Quality  
---|---  
CIRS is a distinct, diagnosable clinical entity with reproducible biomarkers | **Moderate** — Primarily Shoemaker group publications; limited independent replication  
Urine mycotoxin testing reflects tissue burden and guides treatment | **Weak** — Commercial labs; no validated reference ranges; dietary confounding  
The Shoemaker 12-step protocol is the only effective treatment | **Moderate** — Best-documented in literature, but virtually all from one research group  
VCS testing is a reliable screening tool for biotoxin illness | **Moderate** — Functional screen with clinical utility, but not specific to CIRS (other neuro-ophthalmic conditions cause VCS deficits)  
Environmental ERMI scores reliably predict patient illness | **Moderate** — Association exists, but false negatives (actinobacteria) and false positives complicate clinical use  
  
### Key Skeptical References

  * **Chang & Gershwin (2019)** — Independent critical review concluding that evidence does not support "toxic mold syndrome" as defined by Shoemaker; criticized commercial mycotoxin testing laboratories as lacking scientific credibility
  * **American College of Medical Toxicology (2025)** — Position statement questioning clinical validity of urine mycotoxin testing
  * **Hurraß (2024)** — German scientific medical societies mold guideline (updated 2024)
  * **Karhuvaara (2024)** — Independent biomarker study with mixed findings



> **Assessment per Source Evaluation Framework:** The epidemiology of damp-building health effects is solid (T4–T5: epidemiological + WHO/IARC consensus). The CIRS diagnostic framework is promising but not yet independently validated at scale (T2–T3: human biomarker signal primarily from one research group). Treatment evidence is Level IV–VI (case series, small RCTs) — meaningful for clinical practice but requiring independent replication.

* * *

## Practical Notes

### For Clinicians

  * **Screen broadly:** Any patient with medically unexplained multisystem symptoms (fatigue, cognitive issues, chronic pain, respiratory complaints, mood changes) living or working in a water-damaged building should be screened for CIRS
  * **Studies started with VCS + symptom clusters** — low-cost, non-invasive
  * **Do not rely on urine mycotoxin testing alone** — order the full Shoemaker biomarker panel through Quest/LabCorp
  * **Cholestyramine first** — after confirmed exposure removal, CSM is the foundational intervention
  * **VIP is the last step** — premature VIP use without correcting upstream steps can cause harm



### For Patients

  * **Remediation first** — No treatment protocol works if you continue living in the moldy environment. This often means professional remediation or relocation.
  * **ERMI/HERTSMI-2** — Dust-based testing gives a snapshot of cumulative mold burden; combine with visual inspection by certified inspector (IICRC)
  * **Patience** — The full Shoemaker Protocol takes 6–18 months; premature skipping of steps leads to treatment failure
  * **Financial burden** — CSM, labs, environmental testing, and especially VIP (compounded) create significant costs; insurance coverage is inconsistent



### Cross-References in This library

  * [Stealth Pathogens](stealth-pathogens.html) — CIRS overlaps with chronic Lyme, cell-wall-deficient bacteria, and biofilm-mediated illness
  * [Lyme and Co-infections](lyme-and-co-infections.html) — Post-treatment Lyme disease syndrome shares transcriptomic signatures with CIRS
  * [Biofilms Overview](biofilms-and-chronic-infection-overview.html) — MARCoNS (nasal biofilm infection in CIRS) is a biofilm condition
  * [Biofilm Disruption Protocols](biofilms-and-chronic-infection-overview.html) — EDTA nasal spray for MARCoNS connects to broader biofilm disruption
  * [Mitochondrial Health](mitochondrial-health.html) — CIRS molecular hypometabolism is fundamentally a mitochondrial energy disorder
  * [NAD+ and Sirtuin Activators](nad-and-sirtuin-activators.html) — NAD+ depletion is a common feature; mycotoxin load appears in the NAD+ fatigue differential



* * *

## Sources

1. Dooley M, Vukelic A, Jim L. Chronic inflammatory response syndrome: a review of the evidence of clinical efficacy of treatment. Ann Med Surg . 2024;86(12):7248. PMID: 39649915 . doi 10.1097/MS9.0000000000002718 (PubMed 39649915, DOI 10.1097/MS9.0000000000002718)
2. Shoemaker RC, House DE. Sick building syndrome and exposure to water-damaged buildings: time series study, clinical trial and mechanisms. Neurotoxicol Teratol . 2006;28:573–588. PMID: 17010568 . doi 10.1016/j.ntt.2006.07.003 (PubMed 17010568, DOI 10.1016/j.ntt.2006.07.003)
3. Shoemaker RC, House D, Ryan JC. Structural brain abnormalities in patients with inflammatory illness acquired following exposure to water-damaged buildings. Neurotoxicol Teratol . 2014;45:18–26. PMID: 24946038 . doi 10.1016/j.ntt.2014.06.004 (PubMed 24946038, DOI 10.1016/j.ntt.2014.06.004)
4. PubMed 38367552 (PubMed 38367552)
5. Ryan JC, Wu Q, Shoemaker RC. Transcriptomic signatures in whole blood of patients with CIRS following exposure to ciguatoxin. BMC Med Genom . 2015;8:15. PMID: 25889530 . doi 10.1186/s12920-015-0089-x (PubMed 25889530, DOI 10.1186/s12920-015-0089-x)
6. Dooley M. Biomarkers over Time: From Visual Contrast Sensitivity to Transcriptomics in Differentiating CIRS and ME/CFS. Int J Mol Sci . 2025;26(15):7284. PMID: 40806417 . doi 10.3390/ijms26157284 (PubMed 40806417, DOI 10.3390/ijms26157284)
7. WHO. Guidelines for Indoor Air Quality: Dampness and Mould. 2009. PMID: 23785740 . (PubMed 23785740)
8. Shoemaker RC, Katz D, Ackerly M, et al. Intranasal VIP safely restores volume to multiple grey matter nuclei in patients with CIRS. Intern Med Rev . 2017;3:1–14. doi 10.18103/imr.v3i4.412 (DOI 10.18103/imr.v3i4.412)